Johnson & Johnson Receives FDA De Novo Authorization for OTTAVA™ Robotic Surgical System, Marking a New Era in Robotic-Assisted Surgery
Johnson & Johnson has achieved a major milestone in the field of surgical innovation after the U.S. Food and Drug Administration (FDA) granted De Novo authorization for the company’s OTTAVA™ Robotic Surgical System. The authorization allows Johnson & Johnson to market the next-generation robotic platform for a broad range of general surgery procedures, introducing what the company describes as the world’s first table-integrated robotic system specifically designed for soft tissue surgery.
The FDA’s decision represents a significant advancement in robotic-assisted surgery, providing surgeons and hospitals with a new platform designed to improve operating room efficiency, streamline surgical workflows, and support increasingly data-driven clinical decision-making. Unlike traditional robotic systems that rely on large floor-mounted carts or overhead boom structures, OTTAVA integrates its robotic arms directly into the operating table, creating a more compact surgical environment while maintaining access to advanced robotic capabilities.
The authorization also positions Johnson & Johnson as a stronger competitor in the rapidly expanding global surgical robotics market, an area that continues to experience significant growth as healthcare providers increasingly adopt minimally invasive procedures supported by advanced digital technologies.
FDA Authorizes OTTAVA for Multiple General Surgery Procedures
The FDA granted De Novo authorization for the OTTAVA Robotic Surgical System across numerous soft tissue procedures performed in general surgery.
Approved indications include:
- Roux-en-Y gastric bypass
- Gastrectomy
- Gastric sleeve procedures
- Cholecystectomy
- Splenectomy
- Small bowel resection
- Appendectomy
- Lysis of adhesions
- Fundoplication
- Hiatal hernia repair
Receiving De Novo authorization is particularly significant because it is reserved for novel medical devices that have no substantially equivalent legally marketed predecessor. The designation establishes a new regulatory classification while confirming that the technology has demonstrated an appropriate balance of safety and effectiveness for its intended use.
This authorization lays the regulatory foundation for future product expansion while enabling Johnson & Johnson to begin commercialization within the United States.
Commercial Launch to Begin with Select U.S. Healthcare Institutions
Following regulatory authorization, Johnson & Johnson plans to initiate a phased commercial rollout of the OTTAVA platform.
Rather than pursuing immediate nationwide deployment, the company intends to work initially with a limited number of carefully selected healthcare organizations across the United States. This measured introduction will allow clinical teams to gain experience with the technology while enabling Johnson & Johnson to collect operational feedback and optimize implementation strategies.
The company also intends to expand regulatory approvals internationally while pursuing additional surgical indications over time.
One important component of that expansion is an ongoing U.S. clinical trial evaluating the use of OTTAVA in inguinal hernia repair procedures, potentially broadening the system’s clinical applications in future regulatory submissions.
Creating a New Generation of Surgical Robotics
Johnson & Johnson executives described OTTAVA as more than simply another robotic surgery platform.
According to Tim Schmid, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, the system represents the beginning of an entirely new chapter in robotic-assisted surgery.
He explained that the company’s vision extends beyond introducing another surgical robot. Instead, OTTAVA has been developed as a technology platform capable of transforming surgical care through integration of robotics, digital technologies, clinical intelligence, and advanced workflow automation.
The long-term objective is to support safer, smarter, and more efficient surgical care while enabling surgeons to benefit from connected technologies that continue evolving over time.
A Fundamentally Different System Architecture
One of OTTAVA’s defining innovations is its table-integrated architecture.
Traditional robotic surgical systems typically occupy substantial operating room space through the use of independent robotic towers or large mobile carts positioned around the patient.
OTTAVA approaches the problem differently.
Its robotic arms are fully integrated into the operating room table itself, eliminating the need for separate robotic platforms positioned around the patient.
According to Johnson & Johnson, this design reduces the system’s overall footprint by approximately 30% to 50% compared with conventional multi-port robotic systems.
The smaller footprint creates several practical advantages.
Operating room staff have greater freedom of movement around the patient, surgeons experience improved visibility, communication among surgical teams may become easier, and hospitals may be able to optimize existing operating room layouts without extensive infrastructure modifications.
The design also supports greater flexibility for future operating room modernization initiatives.
Automation Designed to Simplify Surgery
Automation is another core feature of the OTTAVA platform.
The robotic system incorporates sophisticated software that coordinates the movement of four robotic arms integrated into the surgical table.
Rather than requiring extensive manual positioning before every procedure, the system can automatically move into predefined procedural configurations, helping reduce setup time while simplifying operating room preparation.
A unique capability known as Twin Motion enables synchronized movement between the operating table and robotic arms.
This coordinated motion allows surgeons to reposition patients during surgery while maintaining stable instrument orientation and continuous access to multiple anatomical regions.
As a result, procedures involving different surgical quadrants may require fewer interruptions and less manual repositioning than conventional robotic systems.
Next-Generation Surgical Instruments
Johnson & Johnson has also redesigned many of the surgical instruments used with OTTAVA.
Drawing on decades of experience in open surgery and laparoscopic procedures, engineers developed robotic instruments intended to improve precision while addressing challenges commonly encountered during minimally invasive surgery.
Among the innovations is a two-in-one robotic needle driver designed to reduce unintended suture cutting during tissue closure.
The platform also includes advanced monopolar curved scissors engineered to provide consistent cutting performance throughout procedures.
These instruments reflect the company’s effort to optimize not only robotic movement but also the performance of individual surgical tools.
Digital Connectivity Through the Polyphonic™ Ecosystem
Modern surgery increasingly relies on data as much as mechanical precision.
Recognizing this shift, Johnson & Johnson designed OTTAVA to connect directly with its Polyphonic™ digital ecosystem.
Polyphonic serves as a secure digital platform integrating multiple aspects of surgical care into a unified environment.
The system supports:
- Surgical education
- Procedural planning
- Clinical media management
- Data analytics
- Performance insights
- Continuous quality improvement
Rather than functioning solely as a robotic device, OTTAVA becomes part of a broader digital surgical infrastructure capable of generating meaningful insights throughout the surgical journey.
The long-term vision is to support increasingly personalized, evidence-based surgical care by making data more accessible to clinicians and healthcare organizations.
Supporting Surgical Education
Johnson & Johnson also emphasized education as a central component of the OTTAVA platform.
The company has developed a comprehensive learning program intended for both experienced robotic surgeons and clinicians adopting robotic surgery for the first time.
The educational curriculum includes:
- Virtual learning modules
- Hands-on simulation
- Immersive procedural training
- Clinical mentoring
- Ongoing performance support
The program was developed in collaboration with practicing surgeons, educational specialists, and professional surgical societies to encourage consistent technique and safe adoption of robotic-assisted procedures.
As robotic surgery becomes increasingly common worldwide, structured training programs are expected to play a growing role in ensuring procedural quality and patient safety.
Addressing Changing Needs in Modern Operating Rooms
Hospitals continue facing growing pressure to improve efficiency while delivering increasingly complex surgical care.
Operating room capacity, staffing shortages, workflow optimization, and infrastructure limitations have become major concerns across healthcare systems.
Johnson & Johnson designed OTTAVA specifically with these operational realities in mind.
The system aims to help healthcare organizations:
- Improve operating room efficiency
- Maximize available clinical space
- Simplify robotic workflow
- Expand access to robotic-assisted surgery
- Enhance surgical team collaboration
- Improve visibility into procedural data
These objectives extend beyond individual surgical outcomes and reflect broader healthcare efforts to optimize resource utilization while maintaining high standards of patient care.
Integrating Data with Surgical Decision-Making
Peter Schulam, M.D., Ph.D., Chief Scientific Officer for MedTech at Johnson & Johnson, highlighted another important aspect of the company’s long-term vision.
He noted that although robotic surgery has already enhanced surgical precision, considerable variability in patient outcomes remains across healthcare systems.
According to Schulam, the future of surgery depends not only on improved robotics but also on integrating meaningful clinical data into every stage of patient care.
OTTAVA was therefore designed to connect surgical technologies with digital intelligence, allowing surgeons to access insights that may help guide decision-making before, during, and after procedures.
This approach reflects the growing role of artificial intelligence, machine learning, and data analytics in modern surgical practice.
Strengthening Johnson & Johnson’s Position in Surgical Robotics
The FDA authorization significantly strengthens Johnson & Johnson’s presence within the competitive robotic surgery landscape.
The global market continues expanding as hospitals seek minimally invasive technologies capable of improving patient outcomes while supporting operational efficiency.
With OTTAVA, Johnson & Johnson introduces a differentiated platform emphasizing compact design, workflow automation, integrated digital connectivity, and future scalability.
As commercialization progresses, additional regulatory approvals, expanded clinical indications, and continued technological enhancements are expected to broaden the system’s adoption across multiple surgical specialties.
The FDA’s De Novo authorization of the OTTAVA™ Robotic Surgical System marks an important milestone not only for Johnson & Johnson but also for the evolution of robotic-assisted surgery. By introducing the world’s first table-integrated soft tissue robotic platform, the company seeks to redefine how surgical technologies are integrated into modern operating rooms.
Combining advanced robotics, intelligent automation, innovative instrumentation, digital connectivity, and comprehensive clinical education, OTTAVA is positioned as a next-generation platform designed to meet the changing needs of surgeons, hospitals, and patients alike. As Johnson & Johnson begins its phased commercial launch in the United States and continues expanding clinical research and regulatory activities worldwide, OTTAVA has the potential to influence the future direction of minimally invasive surgery and contribute to more efficient, data-informed, and patient-centered surgical care.
About Surgical Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what’s next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit https://www.jnjmedtech.com/en-US/.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.